98%
921
2 minutes
20
Background: People living with human immunodeficiency virus (HIV) (PLWH) have increased risk of developing diastolic dysfunction (DD) and heart failure with preserved ejection fraction (EF). In this observational study, we evaluated DD and left ventricular hypertrophy (LVH) in PLWH receiving antiretroviral therapy (ART) with undetectable viremia.
Methods: We conducted an observational study. All participants underwent transthoracic echocardiography to assess chamber size and systolic and diastolic function.
Results: Most patients showed concentric remodeling without LVH. All patients had normal left ventricle systolic function (EF median 61.3%, interquartile range: 57.8-66.2). None fulfilled the DD criteria, while two patients (6%) had undetermined diastolic function. Twenty percent ( = 7) of patients had an enlarged left atrium (left atrium volume index [LAVI] > 34 cm/m). These patients had a significantly lower CD4 count (771.53 ± 252.81 vs. 446.00 ± 219.02, = 0.01) and higher relative wall thickness (0.50 ± 0.05 vs. 0.44 ± 0.06, = 0.03). Patients without immune restoration above 500 cells/μL had significantly higher LAVI (33.92 ± 6.63 vs. 24.91 ± 7.03, = 0.01).
Conclusions: One-fifth of patients had left atrial enlargement associated with worse immune restoration during ART treatment. The mechanism of left atrial enlargement and its association with cardiovascular risk require further investigations.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10815954 | PMC |
http://dx.doi.org/10.3390/jcm13020463 | DOI Listing |
Ann Am Thorac Soc
September 2025
University of Gothenburg Sahlgrenska Academy, Department of Internal Medicine and Clinical Nutrition, Gothenburg, Sweden.
Introduction: Co-morbid insomnia and sleep apnea (COMISA) has been linked to poorer health outcomes and increased all-cause mortality compared with either insomnia or obstructive sleep apnea (OSA) alone.
Materials And Methods: We investigated the relationship between COMISA and uncontrolled hypertension in the Swedish CardioPulmonary BioImage Study (SCAPIS). A cross-sectional analysis including participants from the SCAPIS Gothenburg cohort (n=3832, 46% males, age 57.
Cardiol Rev
September 2025
From the Department of General Medicine, J.S.S. Medical College, JSS Academy of Higher Education and Research, Mysuru, India.
Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases and is increasing in prevalence due to aging populations and comorbidities such as hypertension and diabetes. While echocardiography remains the diagnostic cornerstone, many patients with preserved ejection fraction present with nonspecific symptoms and ambiguous diastolic indices, leading to diagnostic uncertainty and therapeutic delay. Arterial stiffness-quantified by pulse wave velocity, augmentation index, and cardio-ankle vascular index)-is emerging as a key contributor to HFpEF pathophysiology.
View Article and Find Full Text PDFFront Cardiovasc Med
August 2025
Heart and Vascular Centre, Semmelweis University, Budapest, Hungary.
Objectives: Rheumatoid arthritis (RA) is associated with increased cardiovascular (CV) risk, yet the mechanisms remain unclear. This study aimed to evaluate myocardial structure, function, and tissue characterization using cardiovascular magnetic resonance (CMR) in RA patients and explore associations with RA disease severity.
Methods: This mixed case-control study included 48 RA patients and 34 age- and sex-matched controls.
Front Cardiovasc Med
August 2025
Department of Cardiovascular Medicine, Fengxian Central Hospital, Shanghai, China.
Background: Arterial compliance is an independent predictor of diastolic dysfunction. Invasive catheterization can accurately reflect diastolic function. However, studies on the invasive assessment of diastolic function are currently limited.
View Article and Find Full Text PDFCardiovasc Endocrinol Metab
December 2025
Department of Endocrinology, Scientific Services, USV Pvt. Ltd, Mumbai, Maharashtra, India.
Background: Co-occurrence of type 2 diabetes mellitus (T2DM) and heart failure (HF) elevates the risk of morbidity and mortality. Recent research emphasizes treatment strategies that go beyond glycemic control to enhance heart function.
Aim: To assess the effectiveness and safety of the fixed-drug combination of dapagliflozin and sitagliptin (FDC D/S) in T2DM patients with HF.